Early diagnosis, better prognosis.
We are Reccan, a young medtech company dedicated to improving the prognosis for patients diagnosed with pancreatic cancer.
Our vision
Our vision is to set a standard for early detection of pancreatic cancer and therefore save lives.
We are working to change the trajectory of pancreatic cancer mortality by finding the cancer at an earlier stage than is possible today. Early detection makes interventions and treatments more effective.
Our approach
We are developing an easy-to-use blood test for early detection of pancreatic cancer.
It is highly accurate, non-invasive, and accessible to all physicians in medical care to detect or exclude the presence of cancer.
Our background
Reccan was founded in 2014 by a group of scientists dedicated to the field of pancreatic cancer.
However, the story started years earlier, as one of the founders, Professor Roland Andersson, had the privilege to build and develop a centralized pancreatic surgery service at Lund University Hospital.
This service feeds into translational research, local (institutional) and national registries providing information on improving management and outcome. This work has resulted in a substantial research volume on clinical and translational research with more than 500 international publications presented by the Lund University research group.
The lack of diagnostic biomarkers and limitations with the gold standard tumour marker CA19-9 lead the way to the exploration of tumour biology and biomarkers in pancreatic cancer tissue leading up to the founding of Reccan Diagnostics in 2014.
This very thorough work together with co-founder Professor György Marko-Varga is the backbone for Reccan’s biomarker success.
Our board of directors and founders
Reccan is the product of a team of experienced scientists, partnering up with industry pioneers passionate about changing the outlook of a cancer diagnosis.
-
Roland Andersson
FOUNDER & CHAIRMAN OF THE BOARD
Professor of surgery, Faculty of Medicine at Lund University. He is founder of Reccan Diagnostics AB, as well as other biotech companies. Extensive research and clinical experience.
-
Christine Widstrand
BOARD MEMBER
Christine Widstrand is Executive Vice President at LU Innovation System AB and responsible for the Life Science portfolio. She holds a PhD in Analytical Chemistry from Lund University. With a background as CEO and founder of several Biotech Companies.
-
György Marko-Varga
CO-FOUNDER
Professor and head of the division of clinical protein science and imaging at Lund University, professor at Tokyo Medical University in Japan. He has more than twenty years of experience from Big Pharma, patent applications, novel technological platforms and biobanking.
-
Kirsten Søndersted-Olsen
BOARD MEMBER
Graduated as an executive MBA, originally trained as Export Technician. She has worked with strategic and tactical marketing in the medical devices and IVD business for more than 20 years.
-
Hanna Sjöström
BOARD MEMBER
Hanna Sjöström is educated in economics at Lund University (Master of Business Administration) with specialization in Technology Management. Trained in leadership and strategy within the Executive MBA program by Swedish Management Group, and is a certified board member in Life Sciences. Hanna has held leading positions within large groups such as L'Oréal, the Coca-Cola Company and a leading position at TePe Munhygiensproduker AB.
Our management team
-
Anna Brodén
CHIEF EXECUTIVE OFFICER
MSc in chemical engineering with more than 20 years of experience from renowned pharma and medical technology companies like HemoCue, Allergan and Ferring. Annas key competences lies within project management and business development working in international sales and marketing. Anna’s extensive experience extends to quality and regulatory assurance, underlining her versatility. Anna is dedicated to advancing the life science industry, driven by her enduring passion for the field.
-
Daniel Ansari
SCIENTIFIC ADVISOR
Researcher at Lund University, as well as medical doctor at Skåne University Hospital. Daniel received his PhD in 2014 and has extensive research experience in the field of pancreatic cancer, with special focus on translational research and biomarkers.
-
Peter Holm
IP COUNSEL
Peter Holm is a European Patent Attorney, Partner and Country Manager for Sweden at the patent law firm HØIBERG. Peter is acting as Reccans strategic IP advisor. Peter has a PhD in Biochemistry and Biophysics from Karolinska Institutet, Sweden and has been working as a patent attorney at HØIBERG since 2006, assisting startup companies and individual researchers within the lifescience field.
-
Camilla Drott
QUALITY CONSULTANT
Camilla holds a master’s degree in Industrial Management and Engineering. She is a certified ISO 13485:2016 Lead Auditor with working experience from a Swedish Notified Body. Camilla is experienced in QMS implementation and has profound experience in the medical device lifecycle; from innovation to a CE-marked device and the post market surveillance.